3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
512
Specimen Handling
381
Carboplatin
371
Magnetic Resonance Spectroscopy
333
Cisplatin
327
Nivolumab
302
Cyclophosphamide
295
Radiotherapy
254
Paclitaxel
252
Biopsy
235
Gemcitabine
229
Bevacizumab
212
Dexamethasone
167
durvalumab
162
Oxaliplatin
160
Capecitabine
154
Rituximab
151
Fluorouracil
148
venetoclax
142
atezolizumab
141
Docetaxel
141
Drug Therapy
140
Etoposide
138
Doxorubicin
131
Ipilimumab
125
Radiosurgery
118
Lenalidomide
117
Prednisone
116
Leucovorin
111
fludarabine
109
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Serotonin 5-HT3 Receptor Antagonists
×
1 year
×
Clear all
NCT06780085
2026-05-26
MK-3475-01H
Merck Sharp & Dohme LLC
Phase 2
Recruiting
96 enrolled